Excerpt from this article:
European Medicines Evaluation Agency bans dextropropoxyphene: a landmark decision for clinical toxicology?
Clinical Toxicology Volume 47, 2009 - Issue 8
- There was also an active campaign in Sweden where there was concern about underdetection of associated deaths (6). A decision not to renew a 5-year marketing licence extension had been taken in Spring 2004 and in autumn 2005 dextropropoxyphene became unavailable following a campaign that focussed on its toxicity in overdose (7). Sweden thus lead Europe on this issue."